Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current Medical Research and Opinion

• Publication date

  2010-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1185/03007990903576953PMID 20121655
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amisulpride

  2012cited by this paper
• Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.

  2009cited by this paper
• Predictors of general quality of life and the mediating role of health related quality of life in patients with schizophrenia

  2009cited by this paper
• Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study.

  2009cited by this paper
• Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

  2009cited by this paper
• Management of Patients Presenting with Acute Psychotic Episodes of Schizophrenia

  2009cited by this paper
• Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study.

  2009cited by this paper
• Correlates of Subjective Quality of Life in People With Schizophrenia: Findings From the EuroSC Study

  2008cited by this paper
• Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.

  2008cited by this paper
• Predictors of subjective and objective quality of life in outpatients with schizophrenia

  2008cited by this paper
• A prospective study of Quality of life in schizophrenia in three European countries.

  2007cited by this paper
• Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride

  2007cited by this paper
• Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

  2007cited by this paper
• Measurement of quality of life in schizophrenia: a comparison of two scales

  2007cited by this paper
• Quality Of Life In Schizophrenia On Conventional Versus Atypical Antipsychotic Medication: A Comparative Cross-Sectional Study

  2007cited by this paper
• The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6‐month double‐blind controlled clinical trial

  2006cited by this paper
• Remission and Relapse in the Outpatient Care of Schizophrenia: Three-year Results From the Schizophrenia Outpatient Health Outcomes Study

  2006cited by this paper
• A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression

  2006cited by this paper
• Évaluation comparative de la qualité de vie de patients schizophrènes traités par neuroleptiques classiques et neuroleptiques atypiques : résultats d’une étude transversale

  2006cited by this paper
• Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study

  2006cited by this paper
• [Comparative evaluation of quality of life in patients with schizophrenia treated with conventional versus atypical neuroleptics: results of a transversal study].

  2006cited by this paper
• Atypical Anti-Psychotics in the Real World -A Naturalistic Comparative Outcome Study

  2005cited by this paper
• Subjective versus interviewer assessment of global quality of life among persons with schizophrenia living in the community: A Nordic multicentre study

  2005cited by this paper
• The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

  2005cited by this paper
• Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.

  2005cited by this paper
• The subjective quality of life in deficit and nondeficit schizophrenic patients

  2005cited by this paper
• Quality of life measures in schizophrenia

  2005cited by this paper
• Quality of Life and Response of Negative Symptoms in Schizophrenia to Haloperidol and the Atypical Antipsychotic Remoxipride

  2005cited by this paper
• Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.

  2004cited by this paper
• A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

  2004cited by this paper
• [The subjective quality of life of patients with schizophrenia: influence of psychopathology and patients' expectations. A comparative study].

  2004cited by this paper
• A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation

  2004cited by this paper
• New Antipsychotics, Compliance, Quality of Life, and Subjective Tolerability—Are Patients Better Off?

  2004cited by this paper
• Influence de la psychopathologie et des attentes sur la qualité de vie subjective des patients schizophrènes : une étude comparative

  2004cited by this paper
• Amisulpride

  2004cited by this paper
• Quality of Life Outcomes of Risperidone, Olanzapine, and Typical Antipsychotics Among Schizophrenia Patients Treated in Routine Clinical Practice: A Naturalistic Comparative Study

  2004cited by this paper
• Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.

  2003cited by this paper
• Amisulpride vs Risperidone in Chronic Schizophrenia: Results of a 6-Month, Double-Blind Study

  2003cited by this paper
• Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone.

  2002cited by this paper
• Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride

  2002influential reference
• Patients’ Subjective Experiences of Antipsychotics

  2002cited by this paper
• Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

  2002cited by this paper
• Amisulpride vs. Risperidone in Chronic Schizophrenia: Results of a 6-month Double-blind Study

  2002cited by this paper
• Amisulpride: is there a treatment for negative symptoms in schizophrenia patients?

  2002cited by this paper
• Is olanzapine clinically effective? A naturalistic outcome survey in two hospital settings

  2002cited by this paper
• EQ-SD: a measure of health status from the EuroQol Group

  2001cited by this paper
• A five-year followup study of deficit and nondeficit schizophrenia.

  2001cited by this paper
• Long‐term safety and efficacy of amisulpride in subchronic or chronic schizophrenia

  2000cited by this paper
• Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group*

  2000cited by this paper
• Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.

  2000cited by this paper
• Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

  2000cited by this paper
• Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

  2000cited by this paper
• Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

  2000cited by this paper
• Symptoms and cognition as predictors of community functioning: a prospective analysis.

  1999cited by this paper
• Application and Results of the Manchester Short Assessment of Quality of Life (Mansa)

  1999cited by this paper
• Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability

  1998cited by this paper
• Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

  1997cited by this paper
• Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group.

  1997cited by this paper
• A Brief Mental Health Outcome Scale

  1995cited by this paper
• Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life

  1995cited by this paper
• A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables

  1995cited by this paper
• Revising axis V for DSM-IV: a review of measures of social functioning.

  1992cited by this paper
• Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients.

  1990cited by this paper
• The Functional Status Index: reliability and validity of a self-report functional disability measure.

  1987cited by this paper
• Dr. Goldman replies.

  1984cited by this paper
• Verbal responses to human figure paintings: a test of the uncertainty hypothesis.

  1984cited by this paper
• The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome.

  1984cited by this paper
• Verbal responses to human figure paintings: a test of the uncertainty hypothesis.

  1984cited by this paper

• Association between negative symptoms and health-related quality of life and functional outcomes in persons with schizophrenia: A systematic review.

  2026cites this paper
• Efficacy and Safety of Cariprazine, Asenapine, Xanomeline–Trospium, and Lumateperone for Acute Exacerbations of Schizophrenia in Adults: A Network Meta-Analysis

  2025cites this paper
• Exploring the interplay of psychiatric symptoms, antipsychotic medications, side effects, employment status, and quality of life in Chronic Schizophrenia

  2024cites this paper
• Gender characteristics of schizophrenia remission

  2022cites this paper
• The influence of antipsychotic type (typical vs. atypical) on quality of life among individuals with schizophrenia

  2021cites this paper
• Biopsychosocial Approach for Improving the Quality Life of Persons with Mental Illness: A Case Report from India

  2020cites this paper
• Biopsychosocial Approach for Improving the Quality Life of Persons with Mental Illness: A Case Report from India

  2020cites this paper
• Quality of Life Assessment of Patients Treated with Neuroleptics: A Comparison of Typical and Atypical Antipsychotics

  2019cites this paper
• antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion

  2018cites this paper
• Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion

  2018cites this paper
• antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion

  2018cites this paper
• antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion

  2018cites this paper
• Systematic analysis of transdiagnostic epidemiology and clinical correlates of duration of untreated psychosis in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS)

  2017cites this paper
• Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia

  2016cites this paper
• Switching antipsychotics: Imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-naïve vs. antipsychotic-exposed rats.

  2016cites this paper
• Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial

  2015cites this paper
• Self-perception of quality of life in patients treated with antipsychotics.

  2015cites this paper
• SUSCEPTIBILITY OF DIABETIC HEART TO CATECHOLAMINEINDUCED ARRHYTHMIAS IS INDEPENDENT OF CONTRACTILE DYSFUNCTION OSETLJIVOST SRCA NA KATEHOLAMINIMA IZAZVANE ARITMIJE JE NEZAVISNA OD KONTRAKTILNE DIS

  2014cites this paper
• Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment.

  2014cites this paper
• The Influence of Antipsychotics on the Quality of Life of Patients with Schizophrenia in a Long-stay Psychiatric Facility

  2014cites this paper
• Un modelo explicativo de la calidad de vida en la esquizofrenia:: el papel de la velocidad de procesamiento y los síntomas negativos

  2012cites this paper
• Atypical antipsychotics--effects of amisulpride on salivary secretion and on clozapine-induced sialorrhea.

  2012cites this paper
• [Influence of perceived social support and functioning on the quality of life of patients with schizophrenia and their caregivers].

  2012cites this paper
• Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects

  2012cites this paper
• Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia

  2012cites this paper
• The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions.

  2012cites this paper
• An explanatory model of quality of life in schizophrenia: the role of processing speed and negative symptoms.

  2012cites this paper
• Design, Synthesis, and Pharmacological Evaluation of Novel Antipsychotic Drugs Based on Olanzapine That Display Reduced Weight Gain and Metabolic Side Effects

  2012cites this paper
• Influencia de la percepción de apoyo y del funcionamiento social en la calidad de vida de pacientes con esquizofrenia y sus cuidadores

  2012cites this paper
• Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties

  2011cites this paper